Peptide 401 |
| カタログ番号GC31767 |
ハチ毒由来の強力なマスト細胞脱顆粒因子であるペプチド 401 は、さまざまな平滑筋スパスモーゲン (ヒスタミンおよび 5-HT) の皮内注射による血管透過性の増加を抑制します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 32908-73-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Peptide 401, a potent mast cell degranulating factor from bee venom, suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (histamine, and 5-HT).
Peptide 401 substantially inhibits the oedema provoked by subplantar injection of carrageenin or intra-articular injection of turpentine in the rat. The ED50 of 401 is c. 0.1 mg/kg. The anti-inflammatory effect is assessed by measurement of the increased 125I-albumin content of an injected site in comparison with an uninjected contralateral site. Peptide 401 also suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (histamine, bradykinin, 5-hydroxytryptamine (5-HT), and prostaglandins)[1]. Peptide 401 (MCD peptide) contains 22 residues and occurs in the venom of the common European honey bee to the extent of about 2% by weight . It has powerful anti-inflammatory activity (at doses as low as 0.1 mg/kg) in a variety of animal models, i.e., hind paw oedema in the rat induced by carrageenin or turpentine, adjuvant arthritis in the rat, and increased skin permeability in the rat resulting from subcutaneous injection of bradykinin, prostaglandin E1 kallikrein, histamine and 5- hydroxytryptamine (5-HT). It has a powerful degranulating effect on mast cells and involves the release of histamine and other pharmacologically active agents[2].
[1]. Hanson JM, et al. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br J Pharmacol. 1974 Mar;50(3):383-92. [2]. Banks BE, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) andcompound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350-4.
| Cas No. | 32908-73-9 | SDF | |
| Canonical SMILES | Ile-Lys-Cys-Asn-Cys-Lys-Arg-His-Val-Ile-Lys-Pro-His-Ile-Cys-Arg-Lys-Ile-Cys-Gly-Lys-Asn-NH2 (Disulfide bridge: Cys3-Cys15, Cys5-Cys19) | ||
| Formula | C110H192N40O24S4 | M.Wt | 2587.22 |
| 溶解度 | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3865 mL | 1.9326 mL | 3.8652 mL |
| 5 mM | 0.0773 mL | 0.3865 mL | 0.773 mL |
| 10 mM | 0.0387 mL | 0.1933 mL | 0.3865 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *